Keywords: cytos, candidate, hypertension, vaccine, cuts, morning, bp

Cytos' candidate hypertension vaccine cuts morning BP in Phase IIa assessment

Article | 17 March 2008

Print This

Switzerland-based Cytos Biotechnology AG says that data from a trial of a developmental hypertension vaccine, CYT006-AngQb, indicate that the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in